Debut Biotech’s proprietary continuous technology overcomes traditional biomanufacturing barriers through a cell-free approach — retaining enzymes and other useful parts of cells, while discarding limiting parts. By working with vital cell enzymes under optimum conditions, Debut Biotech engineers optimized reactions, synthesizing stable targets with high purity. The result is the efficient and continuous manufacturing of biomaterials and other active ingredient products previously overlooked due to low material yields.
